Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
121.9 EUR | 0.00% | 0.00% | 0.00% |
23/04 | Reply S.P.A. Approves the Dividend, Payable on 22 May 2024 | CI |
22/04 | Laife Reply Develosd, in Collaboration with IEO (European Institute of Oncology), the Value Based Medicine, a Web Platform | CI |
Sales 2024 * | 2.29B 2.45B 205B | Sales 2025 * | 2.56B 2.74B 228B | Capitalization | 4.59B 4.91B 410B |
---|---|---|---|---|---|
Net income 2024 * | 211M 226M 18.87B | Net income 2025 * | 236M 253M 21.1B | EV / Sales 2024 * | 1.85 x |
Net cash position 2024 * | 357M 382M 31.89B | Net cash position 2025 * | 548M 587M 49B | EV / Sales 2025 * | 1.58 x |
P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
19.1
x | Employees | - |
Yield 2024 * |
0.86% | Yield 2025 * |
1.03% | Free-Float | 59.89% |
Managers | Title | Age | Since |
---|---|---|---|
Mario Rizzante
CEO | Chief Executive Officer | 75 | 01/96/01 |
Tatiana Rizzante
CEO | Chief Executive Officer | 54 | 01/03/01 |
Director/Board Member | 67 | 01/11/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 01/11/01 | |
Tatiana Rizzante
CEO | Chief Executive Officer | 54 | 01/03/01 |
Mario Rizzante
CEO | Chief Executive Officer | 75 | 01/96/01 |
1st Jan change | Capi. | |
---|---|---|
-2.45% | 33.22B | |
+0.16% | 15.14B | |
-5.82% | 8.95B | |
+2.03% | 7.03B | |
-45.08% | 4.47B | |
+10.38% | 2.94B | |
+5.84% | 2.43B | |
-11.35% | 2.42B | |
-12.49% | 2.13B |